• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094).
  

PubMed=10557056; DOI=10.1038/sj.leu.2401563
Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.
Detection of MUM1/IRF4-IgH fusion in multiple myeloma.
Leukemia 13:1812-1816(1999)

PubMed=19718049; DOI=10.1038/onc.2009.257; PMCID=PMC2844406
Seckinger A., Meissner T., Moreaux J., Goldschmidt H., Fuhler G.M., Benner A., Hundemer M., Reme T., Shaughnessy J.D. Jr., Barlogie B., Bertsch U., Hillengass J., Ho A.D., Pantesco V., Jauch A., De Vos J., Rossi J.-F., Mohler T., Klein B., Hose D.
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Oncogene 28:3866-3879(2009)

PubMed=21173094; DOI=10.3324/haematol.2010.033456; PMCID=PMC3069235
Moreaux J., Klein B., Bataille F.-R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=30545397; DOI=10.1186/s13045-018-0679-0; PMCID=PMC6293660
Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C.
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
J. Hematol. Oncol. 11:137.1-137.13(2018)